Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event was celebrated in the company of Medisca’s valued Plattsburgh team, business partners, and state and federal officials, including Congresswoman Elise Stefanik, Senator Dan Stec, and Assemblyman Billy Jones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627482773/en/
Left to right: Mitchell Rubin, Medisca CFO | Assemblyman Billy Jones | Stephane Nizri, Medisca Head of Engineering | Sanjay Goorachurn, Medisca CEO | Antonio Dos Santos, Medisca Founder and Chairman | Maria Zaccardo, Medisca Co-Founder and Vice-Chair | Congresswoman Elise Stefanik | Panagiota Danopoulos, Medisca SVP Global Strategy and Innovation | Senator Dan Stec | Larry Harney, Medisca Operations Manager (Photo: Business Wire)
"This event marks the completion of the largest project ever undertaken by Medisca in our 35-year history," said Antonio Dos Santos, Medisca Founder and Chairman. “This new facility showcases the diligent efforts and dedication of Medisca people and demonstrates our commitment to supporting the growing demands in personalized medicine."
Continued investment in the North Country
After 32 years of established standing and investment in the North Country, the opening of the new Medisca facility in Plattsburgh exemplifies the value of the workforce in this region.
"The new Medisca facility is a testament to our local workforce talent pool, already providing 65 good-paying local jobs with plans for further expansion," said Congresswoman Elise Stefanik. "This significant investment in Plattsburgh underscores the strength of our region. I am proud to support Medisca and the many industries investing in our community and driving economic prosperity for hardworking families in Upstate and the North Country."
Doubling capacity to serve the growing demands in personalized medicine
Consolidating existing operations into a single site equipped with innovative machinery and automated workflows, the new facility will significantly enhance the company’s capacity to support the diverse healthcare groups it serves.
“In particular, the new facility will allow Medisca to expand its capacity to provide quality products to pharmacists and healthcare professionals, so they can prepare personalized and essential medications for patients like you and me – not just here in the United States, but across the globe,” said Sanjay Goorachurn, Medisca CEO.
Leveraging scalable innovation, reinforcing established quality systems, and prioritizing the health, safety, and wellness of Medisca personnel were paramount in every decision made during the design and construction of the new facility. Key considerations included introducing custom-tailored ISO-rated production rooms and leveraging customized warehouse management systems for end-to-end traceability.
“Taken together, the new facility is a state-of-the-art example that leverages innovation and rigorous quality and safety measures to protect our product, personnel, and environment,” said Dos Santos.
The new Medisca Plattsburgh facility has undergone a successful New York State inspection and third-party documentation and systems audit, with additional licensures and agency inspections actively underway to serve the United States and Global markets. For a look at the new facility, click here.
About Medisca
Founded in 1989, Medisca is a global leader in personalized medicine and pharmaceutical supply chain solutions. Its vast portfolio of over 2,000 products is complemented by a library of 10,000+ proprietary and customized medication formulas, expertise, and services in pharmaceutical compounding, continuing healthcare education, analytical testing, and more. Providing finely-tuned solutions to diverse wellness sectors across the globe, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627482773/en/
Contacts
Medisca Communications
communications@medisca.com
1-800-665-6334
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 14:03:00 CET | Press Release
Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant delivery capability. Coulson’s 767 VLAT is being developed to address
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom